Filing Flows › Comparisons › AWHL vs IMDX
Aspira Women's Health vs Insight Molecular Diagnostics: AWHL and IMDX compared
Aspira Women's Health is the larger company: $2.0M of revenue in its latest quarter (Q2 2026) against $239K for Insight Molecular Diagnostics (Q2 2026). Aspira Women's Health is growing faster (-15% against -54% a year earlier).
Where the money goes: AWHL and IMDX
Aspira Women's Health (AWHL) · Q2 2026
Aspira Women's Health, Q2 2026: revenue $2.0M (-15% year over year), operating margin -89.7%, net loss $2.4M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
Insight Molecular Diagnostics (IMDX) · Q2 2026
Insight Molecular Diagnostics, Q2 2026: revenue $239K (-54% year over year), net loss $11.3M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.
| Aspira Women's Health (AWHL) | Insight Molecular Diagnostics (IMDX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $2.0M | $239K |
| Revenue growth, Y/Y | -15% | -54% |
| Operating margin | -89.7% | n/m |
| Net earnings | −$2.4M | −$11.3M |
| Net margin | -118.3% | — |
| Operating cash flow | −$2.0M | −$9.3M |
Where the revenue comes from
Insight Molecular Diagnostics
- Laboratory Services: $218K (91%)
- Kitted Products: $21K (9%)
Questions
Which is bigger, Aspira Women's Health or Insight Molecular Diagnostics?
Aspira Women's Health is the larger company: $2.0M of revenue in its latest quarter (Q2 2026) against $239K for Insight Molecular Diagnostics (Q2 2026).
Is Aspira Women's Health or Insight Molecular Diagnostics growing faster?
Aspira Women's Health is growing faster (-15% against -54% a year earlier).
More: Aspira Women's Health earnings · how Aspira Women's Health makes money · Insight Molecular Diagnostics earnings · how Insight Molecular Diagnostics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.